Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE).

MLA

Ison, Michael G., et al. “Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE).” Open Forum Infectious Diseases, vol. 10, no. 7, July 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1093/ofid/ofad314.

APA

Ison, M. G., Weinstein, D. F., Dobryanska, M., Holmes, A., Phelan, A.-M., Li, Y., Gupta, D., Narayan, K., Tosh, K., Hershberger, E., Connolly, L. E., Yalcin, I., Campanaro, E., Hawn, P., Schmidt, P., & Group, for the E. S. (2023). Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE). Open Forum Infectious Diseases, 10(7), 1–12. https://doi.org/10.1093/ofid/ofad314

Chicago

Ison, Michael G, Debra F Weinstein, Marta Dobryanska, Anna Holmes, Anne-Marie Phelan, Yong Li, Deepali Gupta, et al. 2023. “Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE).” Open Forum Infectious Diseases 10 (7): 1–12. doi:10.1093/ofid/ofad314.